{"entity":{"id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","aka":["Octreotide","Lanreotide","Octreotide LAR","Somatostatin analogue"],"tldr":"Monthly injections of a synthetic hormone that both quiets tumour hormone symptoms and slows tumour growth, the first treatment for most neuroendocrine tumours.","summary":"Octreotide (1988) controls carcinoid syndrome; PROMID (2009) showed octreotide LAR delays progression in midgut NETs (TTP 14.3 vs 6.0 months); CLARINET (2014) showed lanreotide improves PFS across enteropancreatic NETs (median not reached vs 18 months, HR 0.47). Standard first-line antiproliferative therapy for SSTR-positive grade 1-2 disease; also premedication against carcinoid crisis.","status":"approved","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Octreotide","links":[{"label":"FDA label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Somatostatin%20analogues"}],"tags":[],"related":[],"cancers":["neuroendocrine","small-intestinal-net","pancreatic-net","lung-net","thymoma"],"sections":[],"technologies":[],"targets":["sstr2"],"drugs":[],"companies":["novartis","ipsen"],"institutions":[],"pathways":[],"terms":["carcinoid-syndrome","prrt-term"],"trials":["promid","clarinet","netter-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Sandostatin LAR, Somatuline Depot","modality":"Peptide hormone analogue (SSTR2 agonist)","mechanism":"SSTR2/5 agonism suppresses hormone secretion and proliferation; PROMID and CLARINET established the antiproliferative effect.","approvals":[{"region":"US","year":1988,"indication":"Carcinoid syndrome symptoms (octreotide)"},{"region":"US","year":2014,"indication":"Unresectable GEP-NETs to improve PFS (lanreotide)"}],"mechanismSteps":["Binds SSTR2 on tumour cell","Inhibits adenylyl cyclase and hormone exocytosis","Cell-cycle arrest via SHP-1/SHP-2 phosphatases","Symptom relief within days; growth slowing over months"],"dosing":{"route":"Deep subcutaneous or intramuscular depot","schedule":"Octreotide LAR 30 mg or lanreotide 120 mg every 4 weeks; short-acting octreotide for breakthrough symptoms","monitoring":"Gallstones, glucose, vitamin B12"},"toxicity":[{"event":"Diarrhoea/steatorrhoea","anyGradePct":26,"note":"CLARINET"},{"event":"Cholelithiasis","anyGradePct":10},{"event":"Hyperglycaemia","anyGradePct":5}],"access":[],"regulatoryEvents":[]},"route":"/drugs/octreotide-lanreotide/","neighbours":{"cancer":[{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/"},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/"},{"id":"multiple-endocrine-neoplasia","kind":"cancer","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/cancers/multiple-endocrine-neoplasia/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/"},{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/"},{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/"}],"target":[{"id":"shp2","kind":"target","name":"SHP2 (PTPN11)","route":"/targets/shp2/"},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"company":[{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}],"term":[{"id":"carcinoid-syndrome","kind":"term","name":"Carcinoid syndrome and carcinoid heart disease","route":"/terms/carcinoid-syndrome/"},{"id":"prrt-term","kind":"term","name":"PRRT (peptide receptor radionuclide therapy)","route":"/terms/prrt-term/"}],"trial":[{"id":"clarinet","kind":"trial","name":"CLARINET","route":"/trials/clarinet/"},{"id":"nct00383708","kind":"trial","name":"Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients","route":"/trials/nct00383708/"},{"id":"nct06807437","kind":"trial","name":"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula","route":"/trials/nct06807437/"},{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/"},{"id":"promid","kind":"trial","name":"PROMID","route":"/trials/promid/"},{"id":"nct00600886","kind":"trial","name":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","route":"/trials/nct00600886/"},{"id":"spinet","kind":"trial","name":"SPINET","route":"/trials/spinet/"}],"drug":[{"id":"paltusotine","kind":"drug","name":"Paltusotine","route":"/drugs/paltusotine/"},{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/"},{"id":"pegvisomant","kind":"drug","name":"Pegvisomant","route":"/drugs/pegvisomant/"},{"id":"telotristat-ethyl","kind":"drug","name":"Telotristat ethyl","route":"/drugs/telotristat-ethyl/"}]}}